Best Time to Buy Glenmark Pharmaceuticals Ltd.

Company at a Glance:

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with operations in over 80 countries and a presence in generics, specialty, and over-the-counter (OTC) products.

Listed among the top 50 Generics and biosimilar companies in the world

Integrated throughout the pharmaceutical value chain, with a strong presence in drug discovery, API, and finished dose formulations.

With drugs in various stages of clinical development, the institute has established research excellence in both novel small molecule and biologics research.

The fastest-growing pharmaceutical company among the top 20 in the Indian pharmaceutical market In terms of volume, it ranks 15th among US generic pharma companies. 14 world-class manufacturing plants

        

Financial Highlights

Criteria	Mar 16	Mar 17	Mar 18	Mar 19	Mar 20	Mar 21	Mar 22	TTM	Chart
Price	795.05	857.75	547.45	653.15	205.85	464.7	442
Sales +	7562	9079	9074	9865	10641	10944	12305	12636.0
Sales Growth(YOY)	15.2%	20.1%	-0.1%	8.7%	7.9%	2.8%	12.4%	0.13
Sales Growth(Cagr-2 YOY)	12.2%	17.6%	9.5%	4.2%	8.3%	5.3%	7.5%	0.07
Profit before tax	1,044	1,491	1,119	1,301	1,096	1,382	1,441	1629.0
PBT Margin	14%	16%	12%	13%	10%	13%	12%	0.13
Tax %	29%	26%	28%	29%	29%	30%	31%
Net Profit	743	1109	804	925	776	970	994	953.0
Net Profit Margin	9.8%	12.2%	8.9%	9.4%	7.3%	8.9%	8.1%	0.08
% Profit Growth YOY	256%	49%	-28%	15%	-16%	25%	2%	-0.04
EPS in Rs	26.33	39.29	28.49	32.78	27.5	34.38	33.37	31.22
Price to earning	30.2	21.8	19.2	19.9	7.5	13.5	13.2	14.88
Consolidated Figures in Rs. Crores

Total Revenue, Net Profit.& Return of equity(ROE) Comparison with Average Values:

Average Total Revenue Annual Cr (Annual | in cr ₹)				Average Net Profit Annual Cr (Annual | in cr ₹)				Average ROE Annual % (Annual | in cr ₹)
1Yrs	3Yrs	5 Yrs	7 Yrs	1Yrs	3Yrs	5 Yrs	7 Yrs	1Yrs	3Yrs	5 Yrs	7 Yrs
12305.0	11961.7	11278.2	10649.1	994.0	972.3	923.6	933	10.36 %	12.29 %	13.79 %	16.3 %

Conclusive Summary:-

• Total Revenue Annual Cr growth is higher than historical averages.
• Net Profit Annual Cr growth is stable compared to historical averages.
• ROE Annual % is growing slower than historical averages.

Valuation & Fundamental Price Target

The market expects 7 % revenue and 7.5% PAT CAGRs over FY22-FY25E along with EBITDA margin at ~18-20%

Maintain BUY with a target price of Rs525/share based on 12x Sep'24E earnings. Over the last five years, the stock has traded at an average P/E of 17.3x.

Technical breakout to Buy 

Technically the stock is a very strong candidate for a good Buy. From 18 Apr '22, Glenmark Pharma successfully formed a Cup & Handle pattern. last week after giving a strong breakout above Rs. 443

Level , sustained for 3 days at the present level of Rs. 464.7.

This good time to buy this stock at this level & buy on dips up to Rs. 412 with a stop loss of Rs. 410.

Technical Tergerget is Rs. 550.

Happy investing.

IDFC LIMITED: Best Opportunity to Buy on yearly High Breakout

IDFC Limited is a financial services holding company based in India. It operates through various subsidiaries, including IDFC First Bank (formerly IDFC Bank), IDFC AMC (asset management company), IDFC Alternatives (private equity and infrastructure), and IDFC Securities.

IDFC Limited is a good buy for 2023 due to its strong fundamentals, customised credit card business, focus on online lending, and exposure in corporate funding, the company offers a strong liability franchise, retail franchise, and an attractive return on embedded value of around 20%.Additionally, India's penetration of life insurance is still low, offering potential for growth. Furthermore, the company has recently been cleared by the Securities and Exchange Board of India, adding to the stability of the stock The stock has also given a HEAD & SHOULDER resistance breakout and bullish candle stick pattern, and is currently trading in the ₹87 range. Market experts are expecting the stock to hit ₹100 and ₹120 in the short to medium term,. Additionally, IDFC Limited has delivered a whopping 65% return to its shareholders in the last six months.

Technically the stock looks good for buy at this level which is recently cross above year high & Head & Shoulder breakout.Very good buy above Rs.88 With stop loss rs. 80. Short  medium term target Rs. 120.

Happy investing.

Breakout with Volume -Lemon Tree Hotel

Lemon Tree Hotels Limited is India’s largest hotel chain in the mid-priced hotel sector, and the third largest overall. THL currently operates ~8,400 rooms in 87 hotels around 52 destinations, in India and out of India. Their brands are Aurika Hotels & Resorts, Lemon Tree Premier, Lemon Tree Hotels, Red Fox Hotels, Keys Prima, Keys Select and Keys Lite. As the current pipeline becomes operational, LTHL will be operating ~10,450 rooms in 106 hotels across 64 destinations, in India and abroad.

 The Leon Tree providing best-in-class cost structure, both in building and operating hotels. In an attempt to offer the best Return on Capital Employed to investors, over the long term.

Technically the stocks looks promising in short term. we recommend to buy this stocks  within range  93-96  with target 103 considering support  Support  87-81. Live Chart